20/20 BioLabs Q1 revenue $0.4M, net loss $2.2M; expects Q2 rebound from firefighter programs

20/20 Biolabs, Inc.

2026-Q1 EPS reported -$0.28 revenue$353,375

Q1 revenue $0.4M vs $0.6M YoY; net loss $2.2M vs $0.8M; gross margin 17.8% vs 29.9%.
Cash $4.2M (vs $1.0M Dec 2025) after $5M private placement; deferred revenue $0.5M.
State-funded firefighter cancer screening programs expected to drive meaningful Q2 revenue; second state committed.
Launched OneTest for Longevity with IBM; exclusive U.S. CKD license from ROKIT Healthcare.
Medicare MCED Screening Act signed Feb 2026; pathway for Medicare coverage by 2028.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.